BIIB Biogen Inc.

Price (delayed)

$266.8

Market cap

$41.06B

P/E Ratio

8.82

Dividend/share

N/A

EPS

$30.26

Enterprise value

$46.66B

Sector: Healthcare
Industry: Drug Manufacturers - General
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Highlights

The P/E is 42% below the 5-year quarterly average of 15.3 and 3.1% below the last 4 quarters average of 9.1
The gross profit is up by 2.2% year-on-year
The company's quick ratio fell by 20% QoQ but it rose by 2.5% YoY
The EPS has contracted by 11% from the previous quarter but it has grown by 7% YoY
The equity has contracted by 23% YoY and by 4.9% from the previous quarter
Biogen's debt has increased by 23% YoY

Key stats

What are the main financial stats of BIIB
Market
Shares outstanding
153.88M
Market cap
$41.06B
Enterprise value
$46.66B
Valuations
Price to earnings (P/E)
8.82
Price to book (P/B)
3.93
Price to sales (P/S)
2.93
EV/EBIT
7.36
EV/EBITDA
6.85
EV/Sales
3.27
Earnings
Revenue
$14.26B
EBIT
$6.34B
EBITDA
$6.82B
Free cash flow
$5.92B
Per share
EPS
$30.26
Free cash flow per share
$37.7
Book value per share
$67.96
Revenue per share
$90.91
TBVPS
$101.05
Balance sheet
Total assets
$24.93B
Total liabilities
$14.19B
Debt
$7.83B
Equity
$10.76B
Working capital
$4.04B
Liquidity
Debt to equity
0.73
Current ratio
2.06
Quick ratio
1.61
Net debt/EBITDA
0.82
Margins
EBITDA margin
47.8%
Gross margin
87.6%
Net margin
35.6%
Operating margin
46.7%
Efficiency
Return on assets
19.6%
Return on equity
42.4%
Return on invested capital
36.9%
Return on capital employed
30%
Return on sales
44.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIIB stock price

How has the Biogen stock price performed over time

Financial performance

How have Biogen's revenue and profit performed over time
Revenue
$14.26B
Gross profit
$12.5B
Operating income
$6.66B
Net income
$5.08B
Gross margin
87.6%
Net margin
35.6%
Biogen's net income has decreased by 14% QoQ and by 6% YoY
Biogen's net margin has decreased by 13% from the previous quarter and by 6% YoY
BIIB's operating income is down by 10% since the previous quarter
Biogen's operating margin has decreased by 8% from the previous quarter

Growth

What is Biogen's growth rate over time

Valuation

What is Biogen stock price valuation
P/E
8.82
P/B
3.93
P/S
2.93
EV/EBIT
7.36
EV/EBITDA
6.85
EV/Sales
3.27
The P/E is 42% below the 5-year quarterly average of 15.3 and 3.1% below the last 4 quarters average of 9.1
The EPS has contracted by 11% from the previous quarter but it has grown by 7% YoY
The equity has contracted by 23% YoY and by 4.9% from the previous quarter
BIIB's price to book (P/B) is 16% lower than its 5-year quarterly average of 4.7 and 4.1% lower than its last 4 quarters average of 4.1
The stock's price to sales (P/S) is 36% less than its 5-year quarterly average of 4.6 and 14% less than its last 4 quarters average of 3.4

Efficiency

How efficient is Biogen business performance
Biogen's return on assets has decreased by 12% QoQ and by 4.4% YoY
The ROIC has contracted by 11% from the previous quarter
The ROS has contracted by 10% from the previous quarter and by 6% YoY
The ROE has contracted by 8% from the previous quarter but it has grown by 6% YoY

Dividends

What is BIIB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIIB.

Financial health

How did Biogen financials performed over time
The total assets is 76% more than the total liabilities
The company's quick ratio fell by 20% QoQ but it rose by 2.5% YoY
The current ratio has contracted by 16% from the previous quarter but it has grown by 8% YoY
Biogen's debt is 27% less than its equity
The debt to equity has soared by 62% YoY and by 6% from the previous quarter
The equity has contracted by 23% YoY and by 4.9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.